CVS points finger back at pharma for drug prices

In the latest tussle between pharma and pharmacy benefit managers, a CVS Health Corp. report finds almost flat drug pricing growth for its pharmacy benefit management clients at 0.2%, against manufacturer price growth of 8.3% for specialty brands and 9.2% for "traditional" brands.